Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.
Cindy TraboulsiFares AyoubAlexa SilfenTina G RodriguezDavid T RubinPublished in: Digestive diseases and sciences (2022)
Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis. Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. However, real-world data are lacking. We present a short report on our experience with off-label upadacitinib in patients with CD at a tertiary center. In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.
Keyphrases
- rheumatoid arthritis
- phase ii
- ulcerative colitis
- clinical trial
- end stage renal disease
- electronic health record
- newly diagnosed
- ejection fraction
- chronic kidney disease
- disease activity
- randomized controlled trial
- prognostic factors
- big data
- nk cells
- early onset
- machine learning
- combination therapy
- interstitial lung disease
- deep learning
- patient reported outcomes